BV MAZOVIA

Research code: BV MAZOVIA
Research name: Observational study. Efficacy and safety of brentuximab vedotin (BV) consolidation treatment of patients with Hodgkin’s lymphoma (HL) undergoing autologous haematopoietic cell transplantation (ASCT). A prospective, multicentre observational research.
Indication: lymphoma
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: patients with Hodgkin’s lymphoma (HL) undergoing autologous haematopoietic cell transplantation (ASCT)
Investigated drug: OBSERVATION RESEARCH